Yongding Wu

813 total citations · 1 hit paper
27 papers, 587 citations indexed

About

Yongding Wu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yongding Wu has authored 27 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Yongding Wu's work include Prostate Cancer Treatment and Research (7 papers), RNA modifications and cancer (6 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Yongding Wu is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), RNA modifications and cancer (6 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Yongding Wu collaborates with scholars based in China, United States and Macao. Yongding Wu's co-authors include Weide Zhong, Yuxiang Liang, Funeng Jiang, Huichan He, Sheng-Bang Yang, Zhaodong Han, Rujun Mo, Zhiduan Cai, Qi-Shan Dai and Guo Chen and has published in prestigious journals such as Nature Communications, Cancer Research and Clinical Cancer Research.

In The Last Decade

Yongding Wu

23 papers receiving 581 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer

2025 17 citations Yinghao Chen, Cheng‐Yu Liao et al. Drug Resistance Updates profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yongding Wu China	14	386	242	155	145	71	27	587
Rui Gou China	16	367 1.0×	248 1.0×	144 0.9×	120 0.8×	69 1.0×	28	547
Yuexin Hu China	16	345 0.9×	247 1.0×	141 0.9×	115 0.8×	65 0.9×	36	527
Erwin Tomasich Austria	13	336 0.9×	187 0.8×	120 0.8×	179 1.2×	72 1.0×	31	547
Huinian Zhou China	10	390 1.0×	207 0.9×	90 0.6×	146 1.0×	53 0.7×	27	559
Misty Shuo Zhang Hong Kong	10	467 1.2×	283 1.2×	167 1.1×	147 1.0×	72 1.0×	13	681
Meng-Xuan Zhu China	10	398 1.0×	235 1.0×	83 0.5×	156 1.1×	128 1.8×	15	582
Po-Lin Lin Taiwan	12	382 1.0×	161 0.7×	78 0.5×	143 1.0×	61 0.9×	17	539
Zhuonan Liu China	8	445 1.2×	159 0.7×	83 0.5×	132 0.9×	53 0.7×	12	529
Inés López Spain	10	396 1.0×	258 1.1×	198 1.3×	280 1.9×	44 0.6×	18	664

Countries citing papers authored by Yongding Wu

Since Specialization

Citations

This map shows the geographic impact of Yongding Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongding Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongding Wu more than expected).

Fields of papers citing papers by Yongding Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongding Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongding Wu. The network helps show where Yongding Wu may publish in the future.

Co-authorship network of co-authors of Yongding Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongding Wu. A scholar is included among the top collaborators of Yongding Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongding Wu. Yongding Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Chun, Yinghao Chen, Zuwei Wang, et al.. (2025). Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Drug Resistance Updates. 83. 101292–101292.

Pan, Yu, Ge Li, Yongding Wu, et al.. (2025). SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Advanced Science. 12(38). e08431–e08431. 1 indexed citations

Liu, Shaoyou, Jian Chen, Xinyue Mei, et al.. (2025). ACACA depletion activates the cPLA2–arachidonic acid–NF-κB axis to drive inflammatory reprogramming in androgen receptor-independent prostate cancer. Cell Communication and Signaling. 23(1). 352–352.

Wu, Yongding, Xiaoxiao Huang, Haoxiang Zhang, et al.. (2025). TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Cancer Research. 85(17). 3292–3312. 1 indexed citations

Chen, Yinghao, Cheng‐Yu Liao, Xiaoxiao Huang, et al.. (2025). Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. Drug Resistance Updates. 81. 101240–101240. 17 indexed citations breakdown →

Deng, Yulin, Zhihao Zou, Wei‐Cheng Tian, et al.. (2025). Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation. Cancer Letters. 622. 217694–217694. 2 indexed citations

Zou, Zhihao, Zhengrong Zhang, Huichan He, et al.. (2024). Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC. Cancer Letters. 605. 217286–217286. 5 indexed citations

Liao, Cheng‐Yu, Yongding Wu, Ge Li, et al.. (2024). Escherichia coli‐Induced cGLIS3‐Mediated Stress Granules Activate the NF‐κB Pathway to Promote Intrahepatic Cholangiocarcinoma Progression. Advanced Science. 11(16). e2306174–e2306174. 14 indexed citations

Liao, Cheng‐Yu, Ge Li, Yongding Wu, et al.. (2024). Necroptosis enhances ‘don’t eat me’ signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Nature Communications. 15(1). 6043–6043. 36 indexed citations

10.

Liao, Cheng‐Yu, Hong-Yi Lin, Yongding Wu, et al.. (2024). Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. Molecular Cancer. 23(1). 215–215. 13 indexed citations

11.

Liao, Cheng‐Yu, Ge Li, Yongding Wu, et al.. (2023). A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM‐STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma. Advanced Science. 10(32). e2303814–e2303814. 20 indexed citations

12.

Hong, Yuan, et al.. (2022). FCGR3A: A new biomarker with potential prognostic value for prostate cancer. Frontiers in Oncology. 12. 1014888–1014888. 3 indexed citations

13.

Han, Zhaodong, Rujun Mo, Yuanfa Feng, et al.. (2022). Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer. Frontiers in Cell and Developmental Biology. 10. 831329–831329. 14 indexed citations

14.

Ye, Jian‐Heng, Zhiduan Cai, Yong Luo, et al.. (2020). GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate. Cancer Research. 80(11). 2150–2162. 51 indexed citations

15.

Cai, Zhiduan, Yulin Deng, Jian‐Heng Ye, et al.. (2020). <p>Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer</p>. Cancer Management and Research. Volume 12. 6149–6163. 21 indexed citations

16.

Jia, Zhenyu, Jianguo Zhu, Yangjia Zhuo, et al.. (2019). Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment. Frontiers in Oncology. 9. 539–539. 7 indexed citations

17.

Zou, Jun, Funeng Jiang, Zhaodong Han, Yanru Chen, & Yongding Wu. (2016). The value of retinoblastoma binding protein 4 in the diagnosis of prostate cancer. Zhonghua miniao waike zazhi. 37(9). 703–706.

18.

Liang, Yuxiang, Jianming Lü, Rujun Mo, et al.. (2016). E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer. International Journal of Oncology. 48(4). 1650–1658. 47 indexed citations

19.

Zhong, Weide, Xin Fu, Guo Chen, et al.. (2016). Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. OncoTargets and Therapy. 9. 2211–2211. 93 indexed citations

20.

Cai, Chao, Zhaodong Han, Yanqiong Zhang, et al.. (2015). miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer. Clinical Cancer Research. 21(21). 4922–4934. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact